Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10612	Companies
225249	Keywords
153884	Articles
119166	Press releases

Home
Companies
Theranexus

BRIEF

published on 10/14/2025 at 18:35, 8 months 7 days ago

THX Pharma et Exeltis progressent vers la mise sur le marché de TX01

Commercialisation Maladies Rares Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 8 months 7 days ago

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis achieve key milestone towards the commercialization of TX01 for rare neurological diseases, including Gaucher and Niemann-Pick type C. A pivotal step towards regulatory submission and global launch

Commercialization Neurological Diseases Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 8 months 7 days ago

THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMMERCIALISATION DE TX01
THX Pharma (Theranexus) et Exeltis franchissent une étape majeure vers la commercialisation de TX01 pour les maladies de Gaucher et de Niemann-Pick de type C. Annonce du dépôt du dossier réglementaire et avancement vers la mise à disposition du traitement pour les patients

Commercialisation Maladies Rares Exeltis TX01 THX Pharma
BRIEF

published on 09/29/2025 at 18:35, 8 months 22 days ago

THX Pharma: a strategic evolution towards international expansion

Growth Strategy Rare Diseases THX Pharma International Marketing Drugs TX01 And Batten-1
BRIEF

published on 09/29/2025 at 18:35, 8 months 22 days ago

THX Pharma : une évolution stratégique vers l'international

Stratégie De Croissance Maladies Rares THX Pharma Commercialisation Internationale Médicaments TX01 Et Batten-1
PRESS RELEASE

published on 09/29/2025 at 18:30, 8 months 22 days ago

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases
THX Pharma (formerly Theranexus) announces strategic focus on regulatory approval, early access, and global commercialization of new drug candidates for rare neurological diseases

Regulatory Approval Commercialization Rare Neurological Diseases THX Pharma Early Access
PRESS RELEASE

published on 09/29/2025 at 18:30, 8 months 22 days ago

Theranexus devient THX Pharma : une évolution stratégique vers la commercialisation de ses médicaments dans les maladies rares
THX Pharma, anciennement Theranexus, annonce sa nouvelle phase stratégique axée sur l'enregistrement, l'accès précoce et la commercialisation internationale de ses médicaments

Candidats Médicaments Maladies Neurologiques Rares THX Pharma Commercialisation Internationale Enregistrement
BRIEF

published on 09/25/2025 at 18:05, 8 months 26 days ago

Theranexus publie ses résultats financiers du premier semestre 2025

Résultats Financiers Theranexus Batten-1 Réduction Coûts TX01
BRIEF

published on 09/25/2025 at 18:05, 8 months 26 days ago

Theranexus publishes its financial results for the first half of 2025

Financial Results Cost Reduction Theranexus Batten-1 TX01
PRESS RELEASE

published on 09/25/2025 at 18:00, 8 months 26 days ago

THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2025
Theranexus publie ses résultats semestriels pour la période se terminant le 30 juin 2025, mettant en avant la réduction des charges d'exploitation et les projets en cours. Prochaine publication financière le 23 octobre 2025

Résultats Semestriels Développement Trésorerie Theranexus Charges D'exploitation

Accesswire

Published on 06/22/2026 at 15:00, 39 minutes ago

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Published on 06/22/2026 at 14:01, 1 hour 38 minutes ago

Worksport (NASDAQ:WKSP) Achieves 35% May Gross Margin, Lands Meyer Distribution, Targets $36M+ Revenue Run-Rate
Published on 06/22/2026 at 14:00, 1 hour 39 minutes ago

Adcore Enters Strategic Partnership with TikTok as a Channel Sales Partner
Published on 06/22/2026 at 14:00, 1 hour 39 minutes ago

Dateline Expands Music Valley HREE Project
Published on 06/22/2026 at 14:00, 1 hour 39 minutes ago

Loop Industries Appoints Institutional Shareholder Jeff Geygan to Board; GVIC Outlines Intent to Increase Ownership Stake to 10%

View all ACCESSWIRE

EQS Group

Published on 06/22/2026 at 15:28, 10 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Personal Finance plc
Published on 06/22/2026 at 15:27, 11 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Gamma Communications plc
Published on 06/22/2026 at 15:26, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: easyJet plc
Published on 06/22/2026 at 15:26, 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 06/22/2026 at 15:25, 13 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited

Les Echos

Published on 06/22/2026 at 14:42, 56 minutes ago

COMMUNIQUE HOPENING 22 juin 2026
Published on 06/22/2026 at 08:30, 7 hours 9 minutes ago

Eiffage entre en négociation exclusive avec Atlas Arteria en vue d’acquérir la concession du tunnel de Warnow à Rostock, en Allemagne
Published on 06/22/2026 at 08:30, 7 hours 9 minutes ago

Eiffage enters into exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany
Published on 06/19/2026 at 19:33, 2 days 20 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days 20 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026

View all LES ECHOS COMFI WIRE